Ken Griffin Uro Gen Pharma Ltd. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$12.7 - $17.92 $176,530 - $249,088	13,900 Added 39.38%	49,200 $624,000
Q2 2024 Aug 14, 2024	BUY	$12.72 - $19.2 $227,688 - $343,680	17,900 Added 102.87%	35,300 $592,000
Q1 2024 May 15, 2024	BUY	$13.81 - $19.33 $17,953 - $25,128	1,300 Added 8.07%	17,400 $261,000
Q4 2023 Feb 14, 2024	BUY	$10.87 - $15.93 $86,960 - $127,440	8,000 Added 98.77%	16,100 $241,000
Q3 2023 Nov 14, 2023	SELL	$8.84 - $22.64 $45,968 - $117,728	-5,200 Reduced 39.1%	8,100 $113,000
Q2 2023 Aug 14, 2023	BUY	$8.75 - $14.29 $15,750 - $25,722	1,800 Added 15.65%	13,300 $137,000
Q1 2023 May 15, 2023	BUY	$7.99 - $11.02 $88,689 - $122,322	11,100 Added 2775.0%	11,500 $106,000
Q4 2022 Feb 14, 2023	BUY	$7.55 - $11.96 $3,020 - $4,784	400 New	400 $3,000

130

35.9M

22K

93.8K

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $254M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.